Literature DB >> 25217972

Clinical research of traditional Chinese medicine in big data era.

Junhua Zhang1, Boli Zhang.   

Abstract

With the advent of big data era, our thinking, technology and methodology are being transformed. Data-intensive scientific discovery based on big data, named "The Fourth Paradigm," has become a new paradigm of scientific research. Along with the development and application of the Internet information technology in the field of healthcare, individual health records, clinical data of diagnosis and treatment, and genomic data have been accumulated dramatically, which generates big data in medical field for clinical research and assessment. With the support of big data, the defects and weakness may be overcome in the methodology of the conventional clinical evaluation based on sampling. Our research target shifts from the "causality inference" to "correlativity analysis." This not only facilitates the evaluation of individualized treatment, disease prediction, prevention and prognosis, but also is suitable for the practice of preventive healthcare and symptom pattern differentiation for treatment in terms of traditional Chinese medicine (TCM), and for the post-marketing evaluation of Chinese patent medicines. To conduct clinical studies involved in big data in TCM domain, top level design is needed and should be performed orderly. The fundamental construction and innovation studies should be strengthened in the sections of data platform creation, data analysis technology and big-data professionals fostering and training.

Entities:  

Mesh:

Year:  2014        PMID: 25217972     DOI: 10.1007/s11684-014-0370-y

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  6 in total

1.  Prevention of coronary and cerebral thrombosis.

Authors:  L L CRAVEN
Journal:  Miss Valley Med J       Date:  1956-09

Review 2.  Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine.

Authors:  Andrea D Weston; Leroy Hood
Journal:  J Proteome Res       Date:  2004 Mar-Apr       Impact factor: 4.466

3.  Why do we need some large, simple randomized trials?

Authors:  S Yusuf; R Collins; R Peto
Journal:  Stat Med       Date:  1984 Oct-Dec       Impact factor: 2.373

4.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

5.  Developing and evaluating complex interventions: the new Medical Research Council guidance.

Authors:  Peter Craig; Paul Dieppe; Sally Macintyre; Susan Michie; Irwin Nazareth; Mark Petticrew
Journal:  BMJ       Date:  2008-09-29

6.  Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial.

Authors:  Hongcai Shang; Junhua Zhang; Chen Yao; Baoyan Liu; Xiumei Gao; Ming Ren; Hongbao Cao; Guohua Dai; Weiliang Weng; Sainan Zhu; Hui Wang; Hongjuan Xu; Boli Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-14       Impact factor: 2.629

  6 in total
  1 in total

1.  Mining Important Herb Combinations of Traditional Chinese Medicine against Hypertension Based on the Symptom-Herb Network Combined with Network Pharmacology.

Authors:  Zhenhai Sun; Yunsheng Xu; Wenrong An; Siling Bi; Sai Xu; Rui Zhang; Mingyang Cong; Shouqiang Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-22       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.